I claim:

25

30

- 1. An axon growth stimulation kit comprising
- a first container means for containing a flowable carrier component or two or more separate components capable once intermingled of forming a flowable carrier component, said flowable carrier components each being capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site and a second container means for containing a therapeutically active agent for facilitating axon growth at thelesion site
 - growth at thelesion site
 wherein said therapeutically active agent is releasable from said in vivo matrix into the
 adjacent external environment.
- 2. An axon growth stimulation kit as defined in claim 1 comprising means for dispersing the therapeutically active agent in said flowable carrier component so as to form a flowable axon growth stimulation composition and means for deliverying the flowable axon growth stimulation composition to the lesion site.
- An axon growth stimulation kit as defined in claim 1 wherein said therapeutically acceptable matrix is a collagen matrix.
 - 4. An axon growth stimulation kit as defined in claim 1 wherein said therapeutically acceptable matrix is a fibrin matrix.
 - A biocompatible composition comprising: (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth; and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the adjacent external environment.

- 6. A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a collagen matrix.
- 7. A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a fibrin matrix.

5

10

- 8. A method for the preparation of a flowable biocompatible composition comprising admixing (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the adjacent external environment.
- 9 A method as defined in claim 8 wherein said therapeutically acceptable matrix is a collagen matrix.
 - 10. A method as defined in claim 8 wherein said therapeutically acceptable matrix is a fibrin matrix.